JP6905993B2 - 置換された二環式ヘテロ環化合物 - Google Patents
置換された二環式ヘテロ環化合物 Download PDFInfo
- Publication number
- JP6905993B2 JP6905993B2 JP2018555138A JP2018555138A JP6905993B2 JP 6905993 B2 JP6905993 B2 JP 6905993B2 JP 2018555138 A JP2018555138 A JP 2018555138A JP 2018555138 A JP2018555138 A JP 2018555138A JP 6905993 B2 JP6905993 B2 JP 6905993B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyridinyl
- oxo
- dihydroisobenzofuran
- pyrazolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C(c1c2cccc1)NOC2=O Chemical compound *C(c1c2cccc1)NOC2=O 0.000 description 4
- MJWJSSJVKAFAAT-UHFFFAOYSA-N CC(C)(C)OC(N(CCc1c2)Cc1ccc2NCc(cc1F)ccc1C#N)=O Chemical compound CC(C)(C)OC(N(CCc1c2)Cc1ccc2NCc(cc1F)ccc1C#N)=O MJWJSSJVKAFAAT-UHFFFAOYSA-N 0.000 description 1
- MDGQYXFTIFQVKD-UHFFFAOYSA-N CC(C)(C)OC(N1Cc2cnc(-[n]3c(cccc4)c4c(C#N)c3)nc2CC1)=O Chemical compound CC(C)(C)OC(N1Cc2cnc(-[n]3c(cccc4)c4c(C#N)c3)nc2CC1)=O MDGQYXFTIFQVKD-UHFFFAOYSA-N 0.000 description 1
- HJZKNNJZQLCFEI-UHFFFAOYSA-N CN(c1cc(Br)ccc1O1)C1=O Chemical compound CN(c1cc(Br)ccc1O1)C1=O HJZKNNJZQLCFEI-UHFFFAOYSA-N 0.000 description 1
- BXAHGSPNVLQIJJ-UHFFFAOYSA-N Cc(cc1)cc(CO2)c1C2=O Chemical compound Cc(cc1)cc(CO2)c1C2=O BXAHGSPNVLQIJJ-UHFFFAOYSA-N 0.000 description 1
- XVWUZRYXGUMHST-UHFFFAOYSA-M Cc(cc1)cc(N2[Rh])c1OC2=O Chemical compound Cc(cc1)cc(N2[Rh])c1OC2=O XVWUZRYXGUMHST-UHFFFAOYSA-M 0.000 description 1
- OITSCQTZUMBONU-UHFFFAOYSA-N Cc1c(COC2=O)c2ccc1C=O Chemical compound Cc1c(COC2=O)c2ccc1C=O OITSCQTZUMBONU-UHFFFAOYSA-N 0.000 description 1
- CHIFTAQVXHNVRW-UHFFFAOYSA-N N#Cc1c[nH]c2c1cccc2 Chemical compound N#Cc1c[nH]c2c1cccc2 CHIFTAQVXHNVRW-UHFFFAOYSA-N 0.000 description 1
- CNTZLIUJUIEFNX-UHFFFAOYSA-N N#Cc1cccc2c1cc[n]2-c1nc(CCN(Cc2ccccc2)C2)c2cn1 Chemical compound N#Cc1cccc2c1cc[n]2-c1nc(CCN(Cc2ccccc2)C2)c2cn1 CNTZLIUJUIEFNX-UHFFFAOYSA-N 0.000 description 1
- UELJROAVNZPHNT-UHFFFAOYSA-N N#Cc1cccc2c1cn[n]2-c1ncc(CNCC2)c2n1 Chemical compound N#Cc1cccc2c1cn[n]2-c1ncc(CNCC2)c2n1 UELJROAVNZPHNT-UHFFFAOYSA-N 0.000 description 1
- OURXKMZTZITQLW-UHFFFAOYSA-N N#Cc1ccnc2c1cn[nH]2 Chemical compound N#Cc1ccnc2c1cn[nH]2 OURXKMZTZITQLW-UHFFFAOYSA-N 0.000 description 1
- RCGPHAUCVGQGBO-UHFFFAOYSA-N O=C1OCc2cc(CCN(CC3)Cc(cc4)c3nc4Cl)ccc12 Chemical compound O=C1OCc2cc(CCN(CC3)Cc(cc4)c3nc4Cl)ccc12 RCGPHAUCVGQGBO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/04—1,2,3-Oxadiazoles; Hydrogenated 1,2,3-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325255P | 2016-04-20 | 2016-04-20 | |
| US62/325,255 | 2016-04-20 | ||
| PCT/US2017/028231 WO2017184662A1 (en) | 2016-04-20 | 2017-04-19 | Substituted bicyclic heterocyclic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515911A JP2019515911A (ja) | 2019-06-13 |
| JP2019515911A5 JP2019515911A5 (enExample) | 2020-04-23 |
| JP6905993B2 true JP6905993B2 (ja) | 2021-07-21 |
Family
ID=59215932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555138A Active JP6905993B2 (ja) | 2016-04-20 | 2017-04-19 | 置換された二環式ヘテロ環化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10851108B2 (enExample) |
| EP (1) | EP3445762B1 (enExample) |
| JP (1) | JP6905993B2 (enExample) |
| KR (1) | KR102417686B1 (enExample) |
| CN (1) | CN109311874B (enExample) |
| AU (1) | AU2017252546B2 (enExample) |
| BR (1) | BR112018071548A2 (enExample) |
| CA (1) | CA3021335A1 (enExample) |
| EA (1) | EA037300B1 (enExample) |
| ES (1) | ES2962315T3 (enExample) |
| IL (1) | IL262448B (enExample) |
| MX (1) | MX381425B (enExample) |
| SG (1) | SG11201809173TA (enExample) |
| WO (1) | WO2017184662A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110139862B (zh) * | 2016-11-03 | 2024-01-16 | 百时美施贵宝公司 | 可用作romk通道抑制剂的经取代的二环杂环衍生物 |
| EP3929194B1 (en) | 2017-06-01 | 2024-04-17 | Bristol-Myers Squibb Company | Substituted nitrogen containing compounds |
| TW202329937A (zh) | 2021-12-03 | 2023-08-01 | 美商英塞特公司 | 雙環胺ｃｋ１２抑制劑 |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| WO2025101780A1 (en) * | 2023-11-08 | 2025-05-15 | Octant, Inc. | Pharmacological correctors of rhodopsin and uses thereof |
| WO2026096386A1 (en) | 2024-10-28 | 2026-05-07 | Octant, Inc. | Pharmacological correctors of rhodopsin and uses thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8824291D0 (en) | 1988-10-17 | 1988-11-23 | Zambeletti Spa L | Novel use |
| DE102004020908A1 (de) | 2004-04-28 | 2005-11-17 | Grünenthal GmbH | Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen |
| US8247556B2 (en) | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
| JP2009514846A (ja) | 2005-11-04 | 2009-04-09 | ファイザー・リミテッド | テトラヒドロナフチリジン誘導体 |
| CA2672167C (en) | 2006-12-14 | 2016-01-26 | Bayer Schering Pharma Aktiengesellschaft | Dihydropyridine derivatives useful as protein kinase inhibitors |
| US8673920B2 (en) | 2009-05-06 | 2014-03-18 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| MX2011012199A (es) | 2009-05-15 | 2011-12-08 | Novartis Ag | Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona. |
| DE102009022896A1 (de) | 2009-05-27 | 2010-12-02 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Piperidine |
| EP2632465B1 (en) | 2010-10-27 | 2015-12-30 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2012058134A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| ES2605164T3 (es) | 2011-08-19 | 2017-03-13 | Merck Sharp & Dohme Corp. | Inhibidores del canal de potasio de la médula renal externa |
| CA2844729A1 (en) | 2011-08-25 | 2013-02-28 | F. Hoffmann-La Roche Ag | Serine/threonine pak1 inhibitors |
| WO2013039802A1 (en) | 2011-09-16 | 2013-03-21 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| EP2771004B1 (en) | 2011-10-25 | 2016-05-18 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| EP2771005B1 (en) | 2011-10-25 | 2016-05-18 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US9493474B2 (en) | 2011-10-31 | 2016-11-15 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| EP2773199B1 (en) | 2011-10-31 | 2019-04-10 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US9108947B2 (en) | 2011-10-31 | 2015-08-18 | Merck Sharp & Dohme Corp. | Inhibitors of the Renal Outer Medullary Potassium channel |
| US9206199B2 (en) | 2011-12-16 | 2015-12-08 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| RU2014129740A (ru) | 2011-12-22 | 2016-02-10 | Ф.Хоффманн-Ля Рош Аг | Производные 2,4-диаминопиримидина в качестве ингибиторов серин/треонин киназы |
| WO2014015495A1 (en) | 2012-07-26 | 2014-01-30 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| AR092031A1 (es) | 2012-07-26 | 2015-03-18 | Merck Sharp & Dohme | Inhibidores del canal de potasio medular externo renal |
| CN104781251B (zh) | 2012-11-08 | 2016-12-14 | 百时美施贵宝公司 | 可作为激酶调节剂的经双环杂环取代的吡啶基化合物 |
| TWI692469B (zh) | 2012-11-09 | 2020-05-01 | 南韓商Ｌｇ化學股份有限公司 | Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
| WO2014085210A1 (en) | 2012-11-29 | 2014-06-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2014089324A1 (en) | 2012-12-07 | 2014-06-12 | Calitor Sciences, Llc | Substituted cyclic compounds and methods of use |
| WO2014099633A2 (en) | 2012-12-19 | 2014-06-26 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| EP2956142B1 (en) | 2013-02-18 | 2017-09-20 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US9765074B2 (en) | 2013-03-15 | 2017-09-19 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| JP6103527B2 (ja) | 2013-04-17 | 2017-03-29 | 矢崎総業株式会社 | 余長吸収装置及びコイルユニット |
| FR3008977A1 (fr) | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US9751881B2 (en) | 2013-07-31 | 2017-09-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US9951052B2 (en) | 2013-10-31 | 2018-04-24 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2015095097A2 (en) * | 2013-12-18 | 2015-06-25 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2015096035A1 (en) | 2013-12-24 | 2015-07-02 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
| WO2015103756A1 (en) | 2014-01-09 | 2015-07-16 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2016010801A1 (en) | 2014-07-14 | 2016-01-21 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2016008064A1 (en) | 2014-07-14 | 2016-01-21 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
| EP3207030A4 (en) | 2014-10-14 | 2018-06-06 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2016065582A1 (en) | 2014-10-30 | 2016-05-06 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2016065603A1 (en) | 2014-10-31 | 2016-05-06 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2016069428A1 (en) | 2014-10-31 | 2016-05-06 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2016065602A1 (en) | 2014-10-31 | 2016-05-06 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
| JP6736816B2 (ja) | 2014-12-08 | 2020-08-05 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | ピリジンカルボキサミド誘導体、それらの製造方法およびそれらの医薬用途 |
| CN105693706B (zh) | 2014-12-10 | 2019-11-22 | 江苏恒瑞医药股份有限公司 | 异苯并呋喃酮类衍生物、其制备方法及其在医药上的应用 |
| WO2016122994A1 (en) | 2015-01-29 | 2016-08-04 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2016127358A1 (en) | 2015-02-12 | 2016-08-18 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
-
2017
- 2017-04-19 EP EP17733156.8A patent/EP3445762B1/en active Active
- 2017-04-19 BR BR112018071548-4A patent/BR112018071548A2/pt not_active Application Discontinuation
- 2017-04-19 MX MX2018012840A patent/MX381425B/es unknown
- 2017-04-19 SG SG11201809173TA patent/SG11201809173TA/en unknown
- 2017-04-19 CN CN201780036983.6A patent/CN109311874B/zh active Active
- 2017-04-19 CA CA3021335A patent/CA3021335A1/en not_active Abandoned
- 2017-04-19 WO PCT/US2017/028231 patent/WO2017184662A1/en not_active Ceased
- 2017-04-19 AU AU2017252546A patent/AU2017252546B2/en not_active Expired - Fee Related
- 2017-04-19 ES ES17733156T patent/ES2962315T3/es active Active
- 2017-04-19 KR KR1020187033099A patent/KR102417686B1/ko active Active
- 2017-04-19 JP JP2018555138A patent/JP6905993B2/ja active Active
- 2017-04-19 US US16/094,288 patent/US10851108B2/en active Active
- 2017-04-19 EA EA201892382A patent/EA037300B1/ru not_active IP Right Cessation
-
2018
- 2018-10-17 IL IL262448A patent/IL262448B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017184662A1 (en) | 2017-10-26 |
| US10851108B2 (en) | 2020-12-01 |
| IL262448A (en) | 2018-12-31 |
| EA037300B1 (ru) | 2021-03-05 |
| IL262448B (en) | 2020-08-31 |
| MX2018012840A (es) | 2019-03-11 |
| EP3445762B1 (en) | 2023-09-13 |
| MX381425B (es) | 2025-03-12 |
| BR112018071548A2 (pt) | 2019-04-16 |
| EA201892382A1 (ru) | 2019-03-29 |
| CN109311874B (zh) | 2021-07-30 |
| KR102417686B1 (ko) | 2022-07-07 |
| SG11201809173TA (en) | 2018-11-29 |
| CA3021335A1 (en) | 2017-10-26 |
| AU2017252546B2 (en) | 2021-07-29 |
| ES2962315T3 (es) | 2024-03-18 |
| US20190127380A1 (en) | 2019-05-02 |
| EP3445762A1 (en) | 2019-02-27 |
| AU2017252546A1 (en) | 2018-12-06 |
| JP2019515911A (ja) | 2019-06-13 |
| KR20180134999A (ko) | 2018-12-19 |
| CN109311874A (zh) | 2019-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101622252B (zh) | 用作axl抑制剂的取代三唑 | |
| DE602004010151T2 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
| CN111712496B (zh) | 作为溴结构域蛋白质抑制剂的化合物和组合物 | |
| CN109311874B (zh) | 经取代的二环杂环化合物 | |
| AU2017287902A1 (en) | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds | |
| CN112638917A (zh) | 作为激酶抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法 | |
| AU2017359023A1 (en) | 3-substituted propionic acids as alpha v integrin inhibitors | |
| JP2014111641A (ja) | Ａｘｌインヒビターとして有用なＮ３−ヘテロアリール置換トリアゾールおよびＮ５−ヘテロアリール置換トリアゾール | |
| AU2017359027A1 (en) | Indazole derivatives as αV integrin antagonists | |
| EP3271361B1 (en) | Tricyclic heterocyclic compounds useful as inhibitors of tnf | |
| EP3271362B1 (en) | Heterocyclic compounds useful as inhibitors of tnf | |
| TW202214233A (zh) | 可做為tlr9抑制劑之經取代雜芳基化合物 | |
| KR20180031773A (ko) | Tnf 알파의 조정제로서 유용한 시클릭 화합물 | |
| AU2017362870A1 (en) | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors | |
| WO2000034277A1 (en) | Sulfonamide compounds and uses thereof as medicines | |
| WO2016040417A1 (en) | Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | |
| JP2025526617A (ja) | ５－ヒドロキシトリプタミン受容体サブタイプ２ｂのアンタゴニスト | |
| CA3249905A1 (en) | Substituted bicyclic heteroaryl compounds useful as TLR9 inhibitors | |
| HK40096547A (en) | Piperazine fused ring-containing derivative, pharmaceutically acceptable salt thereof, preparation method therefor, and use thereof | |
| JP2025526717A (ja) | ＴＧＦ－β阻害剤化合物及びその使用 | |
| WO2025223550A1 (zh) | 吡啶或吡嗪并三环化合物及其药用组合物和应用 | |
| WO2024255412A1 (zh) | 螺杂环化合物及其应用 | |
| TW202539660A (zh) | 作為ＣＢＰ／ｐ３００抑制劑之新穎化合物和含有彼作為活性成分以預防或治療癌症、發炎病症或自體免疫疾病之醫藥組成物 | |
| CN120129683A (zh) | 作为shp2抑制剂的唑衍生物 | |
| HK40046602A (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200316 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200316 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210210 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210426 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210608 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210628 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6905993 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |